Published in J Clin Oncol on February 01, 1988
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma (2010) 1.73
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica (2010) 1.23
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. Haematologica (2013) 0.81
Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients. Leuk Res (2014) 0.80
Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients. Blood Res (2013) 0.79
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res (2010) 0.78
The efficacy of the ribonucleotide reductase inhibitor Didox in preclinical models of AML. PLoS One (2014) 0.77
Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. J Clin Invest (2016) 0.75
Highly refractory acute myeloid leukemia. Wien Klin Wochenschr (2004) 0.75
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep (1966) 8.79
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 4.02
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol (2000) 3.50
Superoxide dismutase as a target for the selective killing of cancer cells. Nature (2000) 3.44
Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol (2001) 3.38
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Emil J Freireich: a pioneer of modern oncology (interview by Sue Silver). Lancet Oncol (2001) 3.02
Flow cytometry in clinical cancer research. Cancer Res (1983) 2.72
Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults. Cancer Chemother Rep (1972) 2.71
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
The nature and control of infections in patients with acute leukemia. Cancer Res (1965) 2.55
Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res (2001) 2.41
The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. Clin Exp Immunol (1970) 2.40
Comparison of touch imprints with aspirate smears for evaluating bone marrow specimens. Am J Clin Pathol (1999) 2.38
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst (1991) 2.38
Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med (1993) 2.09
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
Ticarcillin therapy of infections. Antimicrob Agents Chemother (1973) 2.01
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 1.91
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer (1999) 1.90
Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med (1986) 1.86
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med (1982) 1.85
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol (1995) 1.85
Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica (2000) 1.81
Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia (2003) 1.76
Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics (2004) 1.72
DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res (2001) 1.71
Infrared signature of structures associated with the H+(H2O)n (n = 6 to 27) clusters. Science (2004) 1.71
Non-randomized controls in cancer clinical trials. N Engl J Med (1974) 1.67
Active immunotherapy with B.C.G. for recurrent malignant melanoma. Lancet (1973) 1.66
Causes of death in adults with acute leukemia. Medicine (Baltimore) (1976) 1.65
Cellular DNA content as a marker of neoplasia in man. Am J Med (1980) 1.62
Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer (1988) 1.62
Immunoglobulin on tumor cells and tumor-induced lymphocyte blastogenesis in human acute leukemia. N Engl J Med (1973) 1.57
Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol (1986) 1.54
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol (1999) 1.51
HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood (1988) 1.51
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant (2004) 1.50
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res (1990) 1.50
Mixed-lineage leukemia revisited: acute lymphocytic leukemia with myeloperoxidase-positive blasts by electron microscopy. Blood (1990) 1.49
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia (2012) 1.49
Studies of patients in a laminar air flow unit. Cancer (1969) 1.49
Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood (1992) 1.48
High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant (2007) 1.48
Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin. N Engl J Med (1974) 1.48
Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma (1993) 1.45
Separation and collection of leukocytes. Cancer Res (1965) 1.45
Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood (2001) 1.43
Angiogenesis and leukemia. Leuk Res (2001) 1.42
Factors related to length of complete remission in adult acute leukemia. Cancer (1980) 1.42
Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med (1992) 1.41
Cells capable of colony formation in the peripheral blood of man. Science (1971) 1.40
A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood (1985) 1.39
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol (1993) 1.38
Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med (1971) 1.38
Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia (1996) 1.36
A randomized comparative trial of three aminoglycosides--comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignancies. Medicine (Baltimore) (1979) 1.36
Growth and differentiation in culture of leukemic leukocytes from a patient with acute myelogenous leukemia and re-identification of type-C virus. Proc Natl Acad Sci U S A (1975) 1.36
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol (2005) 1.32
Role of murine tumor models in cancer treatment research. Cancer Res (1986) 1.30
Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med (1987) 1.30
Pulmonary complications of acute leukemia. Cancer (1966) 1.30
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 1.29
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia (2009) 1.28
Studiesof a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. General techniques and preliminary results. Cancer (1968) 1.28
Chemoimmunotherapy of adult acute leukaemia. Prolongation of remission in myeloblastic leukaemia with B.C.G. Lancet (1974) 1.27
Long-term second remissions in acute lymphatic leukemia. Cancer (1975) 1.27
Prognostic correlations and response to treatment in advanced metastatic malignant melanoma. Cancer Res (1974) 1.25
Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med (1984) 1.24
The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood (1965) 1.23
Malignant gingival and skin "infiltrates" in adult leukemia. Oral Surg Oral Med Oral Pathol (1983) 1.23
Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc (2000) 1.23